Linnaeus Developing a G protein-coupled estrogen receptor (GPER) agonist with applicability across a range of cancers. Startup Details Co-Founded by: Todd Ridky and Chris Natale Linnaeus Website Participates in PCI Ventures UPstart Recent News All News Linnaeus Therapeutics announces first patient dosed in its clinical trial of LNS8801 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced cancer Linnaeus remains squarely on the Fast Track to Success Linnaeus Therapeutics announces clinical trial collaboration agreement with Merck to evaluate LNS8801 in combination with KEYTRUDA Celebrating Penn Innovators, Inventors, and Partners
